Policy Watch: 20 Regulatory Updates — June 21, 2026
This Policy Watch covers schedules of controlled substances placement June 2026 updates with 20 key regulatory items. The DEA's recent actions focus on synthetic cannabinoids and other substances. These changes affect clinical relevance and regulatory…
International Cannabis Policies and Their Association with Cannabis Use, Cannabis Use Disorder, and Other Psychiatric Disorders
International cannabis policies shape cannabis use and cannabis use disorder prevalence worldwide. Commercialized legalization is linked to increased cannabis use disorder rates. However, associations with broader psychiatric disorders remain…
Policy Watch: 20 Regulatory Updates — June 19, 2026
This update covers the DEA Schedule I synthetic cannabinoids control update as of June 19, 2026. It details regulatory actions impacting synthetic cannabinoids and related substances. The report informs clinical practice and legal considerations.
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA synthetic cannabinoids Schedule I placement 2026 update includes cumyl-pegaclone, a synthetic cannabinoid now classified under Schedule I. This reflects regulatory efforts to control emerging psychoactive substances with high abuse potential.…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has enacted synthetic ketamine analog regulation by temporarily placing 2-fluorodeschloroketamine in Schedule I. This action highlights the challenges of controlling emerging designer drugs. Clinicians should monitor these regulatory changes…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I
The DEA scheduling benzodiazepine analogs in Schedule I addresses the abuse potential of synthetic benzodiazepines. These substances pose significant clinical risks and regulatory challenges. Clinicians should be vigilant for exposure to these…
Temporary Scheduling of Bromazolam and Novel Benzodiazepines
The temporary scheduling of novel benzodiazepines such as bromazolam reflects regulatory efforts to address emerging abuse risks. This update highlights clinical toxicology concerns and enforcement under the Controlled Substances Act. Clinicians should…
DEA Update on Diphenidine Scheduling in Controlled Substances Act
The DEA scheduling diphenidine update reflects its placement in Schedule I due to high abuse potential and no accepted medical use. This regulatory action highlights challenges in controlling novel synthetic dissociatives. Clinicians should stay informed…
Federal Cannabis Rescheduling: Evidence-Based Policy Over Celebrity Opinion
The debate over federal cannabis rescheduling requires evidence-based policy decisions rather than celebrity-driven discourse. Current Schedule I classification restricts vital clinical research and creates legal barriers that complicate patient access…
FDA Cannabis Products Move from Schedule I to Schedule III Under New DEA Rule
The U.S. Department of Justice has proposed rescheduling FDA-approved cannabis-derived products from Schedule I to Schedule III, recognizing their medical utility while maintaining controlled substance oversight. This cannabis schedule III…